Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eyenovia Inc (EYEN)

Eyenovia Inc (EYEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,085
  • Shares Outstanding, K 86,442
  • Annual Sales, $ 4 K
  • Annual Income, $ -27,260 K
  • EBIT $ -36 M
  • EBITDA $ -34 M
  • 60-Month Beta 1.75
  • Price/Sales 184.12
  • Price/Cash Flow N/A
  • Price/Book 2.15
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.72
  • Most Recent Earnings $-0.11 on 11/12/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 705.98% ( +153.67%)
  • Historical Volatility 371.22%
  • IV Percentile 94%
  • IV Rank 80.78%
  • IV High 873.06% on 06/18/24
  • IV Low 3.67% on 10/15/24
  • Put/Call Vol Ratio 0.11
  • Today's Volume 174
  • Volume Avg (30-Day) 160
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 3,048
  • Open Int (30-Day) 3,412

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.10
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0832 +29.33%
on 11/20/24
0.5905 -81.78%
on 10/29/24
-0.4353 (-80.18%)
since 10/22/24
3-Month
0.0832 +29.33%
on 11/20/24
0.6500 -83.45%
on 08/30/24
-0.4387 (-80.30%)
since 08/22/24
52-Week
0.0832 +29.33%
on 11/20/24
2.5700 -95.81%
on 03/04/24
-1.2424 (-92.03%)
since 11/22/23

Most Recent Stories

More News
Eyenovia, Inc. Secures Debt Payment Deferral from Avenue Capital to Facilitate Strategic Restructuring

Avenue Capital defers Eyenovia's debt payments until February 2025 as the company explores strategic alternatives and reduces costs.Quiver AI SummaryEyenovia, Inc., an ophthalmic technology company, announced...

EYEN : 0.1076 (+2.38%)
Eyenovia Provides Update on Restructuring Efforts

EYEN : 0.1076 (+2.38%)
Eyenovia, Inc. Announces Discontinuation of CHAPERONE Study After Efficacy Endpoint Not Met

Eyenovia's CHAPERONE study is discontinued after failing its primary efficacy endpoint; further evaluation and strategic options are planned.Quiver AI SummaryEyenovia, Inc. announced the discontinuation...

EYEN : 0.1076 (+2.38%)
Eyenovia Provides Update on Phase 3 CHAPERONE Study

EYEN : 0.1076 (+2.38%)
Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

EYEN : 0.1076 (+2.38%)
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

EYEN : 0.1076 (+2.38%)
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®

EYEN : 0.1076 (+2.38%)
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

EYEN : 0.1076 (+2.38%)
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery

/PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into a licensing agreement with...

EYEN : 0.1076 (+2.38%)
Eyenovia Expands Its US Manufacturing Capabilities

Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, California

EYEN : 0.1076 (+2.38%)

Business Summary

Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc....

See More

Key Turning Points

3rd Resistance Point 0.1301
2nd Resistance Point 0.1225
1st Resistance Point 0.1151
Last Price 0.1076
1st Support Level 0.1001
2nd Support Level 0.0925
3rd Support Level 0.0851

See More

52-Week High 2.5700
Fibonacci 61.8% 1.6200
Fibonacci 50% 1.3266
Fibonacci 38.2% 1.0332
Last Price 0.1076
52-Week Low 0.0832

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar